Cargando…

Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization

INTRODUCTION: Monoaminergic activity modulates nociceptive transmission in the central nervous system (CNS). Although pain is the most disabling symptom of osteoarthritis (OA), limited knowledge exists regarding the CNS mechanisms that amplify pain and drive sensitization processes in humans. OBJECT...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjurström, Martin F., Blennow, Kaj, Zetterberg, Henrik, Bodelsson, Mikael, Waldén, Markus, Dietz, Nicholas, Hall, Sara, Hansson, Oskar, Irwin, Michael R., Mattsson-Carlgren, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789209/
https://www.ncbi.nlm.nih.gov/pubmed/35097309
http://dx.doi.org/10.1097/PR9.0000000000000988
_version_ 1784639717525946368
author Bjurström, Martin F.
Blennow, Kaj
Zetterberg, Henrik
Bodelsson, Mikael
Waldén, Markus
Dietz, Nicholas
Hall, Sara
Hansson, Oskar
Irwin, Michael R.
Mattsson-Carlgren, Niklas
author_facet Bjurström, Martin F.
Blennow, Kaj
Zetterberg, Henrik
Bodelsson, Mikael
Waldén, Markus
Dietz, Nicholas
Hall, Sara
Hansson, Oskar
Irwin, Michael R.
Mattsson-Carlgren, Niklas
author_sort Bjurström, Martin F.
collection PubMed
description INTRODUCTION: Monoaminergic activity modulates nociceptive transmission in the central nervous system (CNS). Although pain is the most disabling symptom of osteoarthritis (OA), limited knowledge exists regarding the CNS mechanisms that amplify pain and drive sensitization processes in humans. OBJECTIVES: The main objective of this study was to evaluate associations between cerebrospinal fluid (CSF) monoamine metabolites, pain severity, and central sensitization in patients with OA undergoing total hip arthroplasty (THA). METHODS: Patients with OA (n = 52) and pain-free controls (n = 30) provided CSF samples for measurement of serotonin (5-hydroxyindoleacetic acid [5-HIAA]), noradrenaline (3-methoxy-4-hydroxyphenylglycol [HMPG]), and dopamine (homovanillic acid [HVA]) monoamine metabolites. Patients with OA completed longitudinal evaluation of pain using clinical measures and quantitative sensory testing. RESULTS: Patients with OA had higher HMPG levels when compared with controls (P = 0.036). Within patients with OA undergoing THA, higher 5-HIAA and HVA levels were consistently associated with higher preoperative pain severity. Higher concentrations of 5-HIAA and HVA were also associated with lower conditioned pain modulation levels, whereas higher HMPG levels were linked to more efficient conditioned pain modulation. Patients with higher levels of CSF HVA exhibited increased pressure pain sensitivity (arm pressure pain detection threshold < 250 kPa vs ≥ 250 kPa, P = 0.042). Higher preoperative levels of CSF 5-HIAA predicted poorer pain control 6 months postoperatively (brief pain inventory pain severity; adjusted β = 0.010, 95% CI 0.001–0.019). CONCLUSIONS: In OA patients with disabling pain, higher CSF levels of serotonin and dopamine metabolites are associated with increased pain severity and central sensitization. Increased noradrenergic activity may be associated with more efficient pain inhibitory capacity.
format Online
Article
Text
id pubmed-8789209
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-87892092022-01-27 Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization Bjurström, Martin F. Blennow, Kaj Zetterberg, Henrik Bodelsson, Mikael Waldén, Markus Dietz, Nicholas Hall, Sara Hansson, Oskar Irwin, Michael R. Mattsson-Carlgren, Niklas Pain Rep Musculoskeletal INTRODUCTION: Monoaminergic activity modulates nociceptive transmission in the central nervous system (CNS). Although pain is the most disabling symptom of osteoarthritis (OA), limited knowledge exists regarding the CNS mechanisms that amplify pain and drive sensitization processes in humans. OBJECTIVES: The main objective of this study was to evaluate associations between cerebrospinal fluid (CSF) monoamine metabolites, pain severity, and central sensitization in patients with OA undergoing total hip arthroplasty (THA). METHODS: Patients with OA (n = 52) and pain-free controls (n = 30) provided CSF samples for measurement of serotonin (5-hydroxyindoleacetic acid [5-HIAA]), noradrenaline (3-methoxy-4-hydroxyphenylglycol [HMPG]), and dopamine (homovanillic acid [HVA]) monoamine metabolites. Patients with OA completed longitudinal evaluation of pain using clinical measures and quantitative sensory testing. RESULTS: Patients with OA had higher HMPG levels when compared with controls (P = 0.036). Within patients with OA undergoing THA, higher 5-HIAA and HVA levels were consistently associated with higher preoperative pain severity. Higher concentrations of 5-HIAA and HVA were also associated with lower conditioned pain modulation levels, whereas higher HMPG levels were linked to more efficient conditioned pain modulation. Patients with higher levels of CSF HVA exhibited increased pressure pain sensitivity (arm pressure pain detection threshold < 250 kPa vs ≥ 250 kPa, P = 0.042). Higher preoperative levels of CSF 5-HIAA predicted poorer pain control 6 months postoperatively (brief pain inventory pain severity; adjusted β = 0.010, 95% CI 0.001–0.019). CONCLUSIONS: In OA patients with disabling pain, higher CSF levels of serotonin and dopamine metabolites are associated with increased pain severity and central sensitization. Increased noradrenergic activity may be associated with more efficient pain inhibitory capacity. Wolters Kluwer 2022-01-24 /pmc/articles/PMC8789209/ /pubmed/35097309 http://dx.doi.org/10.1097/PR9.0000000000000988 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Musculoskeletal
Bjurström, Martin F.
Blennow, Kaj
Zetterberg, Henrik
Bodelsson, Mikael
Waldén, Markus
Dietz, Nicholas
Hall, Sara
Hansson, Oskar
Irwin, Michael R.
Mattsson-Carlgren, Niklas
Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization
title Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization
title_full Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization
title_fullStr Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization
title_full_unstemmed Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization
title_short Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization
title_sort central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization
topic Musculoskeletal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789209/
https://www.ncbi.nlm.nih.gov/pubmed/35097309
http://dx.doi.org/10.1097/PR9.0000000000000988
work_keys_str_mv AT bjurstrommartinf centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT blennowkaj centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT zetterberghenrik centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT bodelssonmikael centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT waldenmarkus centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT dietznicholas centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT hallsara centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT hanssonoskar centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT irwinmichaelr centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization
AT mattssoncarlgrenniklas centralnervoussystemmonoaminergicactivityinhiposteoarthritispatientswithdisablingpainassociationswithpainseverityandcentralsensitization